PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsoveractive urinary bladder
MeSH D053201 - overactive urinary bladder
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D001745:Urinary bladder diseases
65 Companies
15 Drugs
$
Success rate
D059411:Lower urinary tract symptoms
0 Companies
0 Drugs
Success rate
D053201: 
Overactive urinary bladder
42 Companies
7 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaSolifenacin Solifenacin  2014-04-02   
PadagisTrospium Trospium  2010-11-17   
Glenmark PharmaceuticalsSolifenacin Solifenacin  2019-05-20   
Trospium Trospium  2010-08-13   
XiromedDarifenacin Darifenacin  2019-10-22   
CiplaDarifenacin Darifenacin  2016-09-01   
Solifenacin Solifenacin  2019-05-20   
Trospium Trospium  2016-08-23   
Lupin ResearchMirabegron Mirabegron  2022-09-28   
AllerganTrospium Sanctura  2004-05-28   
Solifenacin Solifenacin  2019-05-20   
Trospium Trospium  2012-10-12   
PfizerFesoterodine Toviaz  2007-04-20 $146 M Y2022 
Aurobindo PharmaDarifenacin Darifenacin  2016-09-19   
Solifenacin Solifenacin  2022-12-27   
Ajanta PharmaSolifenacin Solifenacin  2019-05-20   
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
48%
10/21
Phase 2
70%
16/23
Phase 3
93%
28/30
Approved: 11Overall Success rate: 31%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Allergan
Solifenacin,
Trospium,
Trospium chloride,
Tartrate,
Aglatimagene besadenovec,
Sodium chloride,
SENREBOTASE
Pfizer
Fesoterodine,
Tartrate,
Estrogens conjugated,
Vitamin e,
Propiverine,
GISADENAFIL
1
2
3
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use